One of the latest developments in the field of anti-cancer immunotherapy is chimeric antigen receptor (CAR) T cell therapy, which is considered magnificent and impressive owing to its superior response rates and efficacy. It has been proven to exhibit great efficacy in curing patients with B cell lymphoma and leukemia, and sometimes multiple myeloma as well. Nevertheless, despite the significant outcomes it has displayed, several limitations and restrictions still deeply restrain CAR T cell therapy from being widely used throughout the world. Particular challenges associated with T cells range from severe cytokine-related toxicities, the on-target off-tumor effect, and antigen escape, to inferior CAR T cell trafficking and immunosuppressive tumor microenvironment. To address the related problems, investigators learn from the evolutions of CAR design and incessantly attempt to modify and ameliorate CAR constructs and launch it to the wider extent of solid tumors and malignancies. A large array of methods and strategies have been adopted by investigators to fulfill this goal, ameliorating the efficacy, security, and applicability of CAR constructs. In this review, we will concentrate on the evolutions of CAR designs, and several limitations CAR T cell therapy recently faces, along with some innovative strategies come up by researchers to tackle them and explore the clinical benefits of this therapy against various cancers.